Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

22.00 +0.39 (+1.83%)

Streaming Delayed Price Updated: 3:16 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher ↗

April 17, 2023

ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else?

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

April 14, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

March 20, 2023

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug ↗

March 14, 2023

The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older.

Via Benzinga

Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment ↗

March 13, 2023

Via Benzinga

1 Top Biotech Stock to Buy in March ↗

March 07, 2023

This biotech could land a major regulatory approval this month.

Via The Motley Fool

Looking Into ACADIA Pharmaceuticals's Return On Capital Employed ↗

March 02, 2023

Via Benzinga

Analysts See Steady Growth For Acadia Pharma's Nuplazid ↗

February 28, 2023

Via Benzinga

Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 14, 2023

Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...

Via Benzinga

Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket ↗

March 13, 2023

Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...

Via Benzinga

3 Nasdaq Stocks on Watch This Week ↗

March 12, 2023

These three Nasdaq stocks are poised to make big moves in the coming week.

Via The Motley Fool

What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

February 28, 2023

Via Benzinga

Earnings Preview For ACADIA Pharmaceuticals ↗

February 24, 2023

Via Benzinga

Analyst Expectations for ACADIA Pharmaceuticals's Future ↗

January 31, 2023

Via Benzinga

Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know ↗

December 21, 2022

Via Benzinga

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗

November 04, 2022

Upgrades

Via Benzinga

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗

September 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review ↗

September 12, 2022

The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory...

Via Benzinga

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

ACADIA Pharmaceuticals's Return On Capital Employed Insights ↗

August 29, 2022

According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ:ACAD) posted sales of $134.56 million. Earnings were up 69.92%, but ACADIA Pharmaceuticals still reported an overall loss of...

Via Benzinga

Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data ↗

August 09, 2022

Via Benzinga

ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees ↗

August 09, 2022

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday.

Via Benzinga

NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday ↗

August 09, 2022

Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to...

Via Benzinga

ACADIA Pharmaceuticals: Q2 Earnings Insights ↗

August 08, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗

August 08, 2022

Via Benzinga

8 Analysts Have This to Say About ACADIA Pharmaceuticals ↗

August 05, 2022

Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter:

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today